ABVC Biopharma Inc (ABVC)vsAlnylam Pharmaceuticals Inc (ALNY)
ABVC
ABVC Biopharma Inc
$1.08
-4.42%
HEALTHCARE · Cap: $27.48M
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 465352% more annual revenue ($3.71B vs $797,920). ALNY leads profitability with a 8.5% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ABVC
Hold38
out of 100
Grade: F
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABVC.
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 375.8%
Revenue surging 104.5% year-over-year
Reasonable price relative to book value
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -119.5% — below average capital efficiency
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABVC
The strongest argument for ABVC centers on Operating Margin, Revenue Growth, Price/Book. Revenue growth of 104.5% demonstrates continued momentum.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : ABVC
The primary concerns for ABVC are EPS Growth, Market Cap, Profit Margin.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
ALNY carries more volatility with a beta of 0.38 — expect wider price swings.
ABVC is growing revenue faster at 104.5% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (49/100 vs 38/100) and 84.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ABVC Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
American BriVision (Holding) Corporation, a clinical-stage biopharmaceutical company, develops drugs and medical devices to meet unmet medical needs in the United States.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?